The House Dust Mite Allergy Market, estimated to be valued at USD 2.96 Billion in 2025, is projected to witness a strong CAGR of 13.8%, reaching USD 7.32 Billion by 2032.
Growth is fueled by the rising prevalence of allergic rhinitis, asthma, and other dust mite–related conditions, alongside the increasing awareness of allergy diagnostics and immunotherapy solutions. Advancements in sublingual and subcutaneous immunotherapy, coupled with the improved availability of over-the-counter antihistamines and corticosteroids, are boosting treatment adoption.
Moreover, expanding healthcare access, regulatory approvals for innovative therapies, and growing investment in R&D for precision medicine approaches are expected to further drive the market expansion globally over the forecast period.
Market Takeaways
House Dust Mite Allergy Market Report Coverage
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/house-dust-mite-allergy-market
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 2.96 Billion |
|
Estimated Value by 2032 |
USD 7.32 Billion |
|
Growth Rate |
Poised to exhibit a CAGR of 13.8% |
|
Historical Data |
2020-2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Trends |
|
|
Opportunities |
|
|
Restraints & Challenges |
|
Market Dynamics
The house dust mite allergy market is experiencing significant growth, driven by the rising global prevalence of allergic rhinitis, asthma, and other respiratory conditions triggered by dust mite exposure. Increasing urbanization, climate change impacts, and poor indoor air quality are amplifying allergen concentrations, leading to higher diagnosis rates. Greater awareness of allergy management, combined with advancements in pharmacotherapy—such as improved antihistamines, nasal corticosteroids, and leukotriene receptor antagonists—is enhancing symptom control and expanding treatment adoption.
A major growth catalyst is the increasing acceptance of allergen-specific immunotherapy, particularly sublingual immunotherapy (SLIT), which offers a convenient, non-invasive alternative to subcutaneous injections. Regulatory approvals of new SLIT tablets in the U.S., Europe, and Asia Pacific, alongside ongoing research into oral immunotherapy and biologics targeting IgE-mediated pathways, are broadening therapeutic options. The integration of advanced diagnostics, such as high-sensitivity skin prick tests and specific IgE blood assays, is facilitating early and accurate detection, enabling timely intervention.
The market is also benefiting from expanding healthcare infrastructure in emerging economies, supportive reimbursement policies in developed countries, and heightened investment in clinical trials for novel allergy therapeutics. However, challenges such as high treatment costs, limited patient adherence to long-term immunotherapy, and regional disparities in access to advanced allergy care may hinder market penetration.
In June 2024, at the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) held in Valencia, Spain (May 31–June 3, 2024), ALK-Abelló A/S unveiled results from two pivotal paediatric Phase 3 clinical trials. The MT-12 trial evaluated the efficacy and safety of the SQ house dust mite (HDM) sublingual immunotherapy (SLIT) tablet in children aged 5–11 years with HDM allergic rhinitis/rhinoconjunctivitis, with or without asthma. The TT-06 trial evaluated the SQ tree SLIT-tablet in children and adolescents aged 5–17 years with moderate to severe allergic rhinitis and/or conjunctivitis caused by birch and related tree pollens. ALK contributed 18 scientific abstracts in total, highlighting its leadership in advancing paediatric allergy immunotherapy research.
Market Trends
There is a growing preference for allergen-specific treatments such as sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT), driven by their disease-modifying potential compared to symptomatic pharmacotherapy. Recent regulatory approvals, including pediatric indications for SLIT tablets, are expanding patient eligibility.
In February 2025, the FDA approved an expanded indication for ALK's House Dust Mite Allergen Tablet (Odactra) to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, to include children aged 5 to 11 years, according to an announcement from ALK.
The adoption of precise diagnostic tools, such as component-resolved diagnostics (CRD) and high-sensitivity specific IgE assays, is enabling the accurate identification of allergens and the development of personalized treatment plans. This trend is supported by the wider availability of rapid point-of-care allergy testing.
In May 2023, Metropolis Healthcare, a leading diagnostic service provider in India, launched an AI-powered Component-Resolved Diagnostics platform capable of testing 127 respiratory, 10 contact, and 158 food allergens. This platform empowers clinicians to make informed treatment decisions through highly precise allergen identification.
Market Opportunities
The rise of AI-powered component-resolved diagnostics (CRD) and multiplex IgE assays creates opportunities for providers to offer precision diagnosis packages linked directly to tailored treatment plans. Partnerships between pharma and diagnostic firms could streamline the “test-to-treat” pathway, improving treatment uptake rates.
In June 2025, innovation introduced the Skin Prick Automated Test (SPAT) device that uses AI and image segmentation for precise wheal detection. The system captures multiple images under varied lighting conditions and applies neural network–based segmentation to increase diagnostic accuracy over conventional single-image methods.
Emerging clinical research and real-world evidence are increasingly supporting the synergistic potential of combining allergen immunotherapy (AIT) with biologics such as anti-IgE (omalizumab), anti-IL-5 (mepolizumab, reslizumab), and anti-IL-4R (dupilumab) agents. This dual approach can accelerate symptom relief, improve asthma control, and enhance long-term disease modification in patients with severe house dust mite (HDM) allergy—particularly those with comorbid allergic asthma or multiple atopic conditions. Biologics can help reduce the initial adverse reactions sometimes associated with AIT initiation, thereby improving patient adherence and enabling higher maintenance doses earlier in therapy.
In high-income markets with favorable reimbursement environments, this strategy represents a premium treatment segment with strong commercial potential. The approach is particularly relevant for difficult-to-treat populations, such as patients with high baseline IgE levels or poor control on standard therapy. Ongoing Phase II and III trials are exploring these combinations, with early findings suggesting improved lung function, reduced exacerbations, and enhanced quality-of-life scores compared to monotherapy. This creates opportunities for pharma–biotech partnerships to develop integrated therapeutic packages, co-marketing strategies, and bundled reimbursement models that could accelerate market adoption once more robust clinical evidence emerges.
Analyst View
Recent Key Developments
In December 2024, Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had provided a positive opinion for the extension of the existing indication for Palforzia (defatted powder of Arachis hypogaea L., semen (peanuts)) to the treatment of toddlers (ages 1 to 3) with a confirmed diagnosis of peanut allergy. If the extension indication is granted by the European Commission, Palforzia will become the first EMA-approved oral immunotherapy (OIT) treatment for toddlers living with confirmed peanut allergy.
Competitive Landscape
House Dust Mite Allergy Market Segmentation
Regional Insights
Related Reports :